IN2009CN03372A - - Google Patents

Download PDF

Info

Publication number
IN2009CN03372A
IN2009CN03372A IN3372CHN2009A IN2009CN03372A IN 2009CN03372 A IN2009CN03372 A IN 2009CN03372A IN 3372CHN2009 A IN3372CHN2009 A IN 3372CHN2009A IN 2009CN03372 A IN2009CN03372 A IN 2009CN03372A
Authority
IN
India
Prior art keywords
protein
canine
tslp
peptide fragments
canine tslp
Prior art date
Application number
Other languages
English (en)
Inventor
Jeanine D Mattson
Daniel M Gorman
Waal Malefyt Rene De
Mohamad A Morsey
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of IN2009CN03372A publication Critical patent/IN2009CN03372A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN3372CHN2009 2006-12-14 2007-12-11 IN2009CN03372A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87513506P 2006-12-14 2006-12-14
PCT/US2007/025318 WO2008076255A2 (en) 2006-12-14 2007-12-11 Canine thymic stromal lymphopoietin protein and uses thereof

Publications (1)

Publication Number Publication Date
IN2009CN03372A true IN2009CN03372A (ja) 2015-08-07

Family

ID=39430681

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3372CHN2009 IN2009CN03372A (ja) 2006-12-14 2007-12-11

Country Status (18)

Country Link
US (3) US7718772B2 (ja)
EP (1) EP2104683B1 (ja)
JP (4) JP2010512744A (ja)
KR (1) KR101525631B1 (ja)
CN (2) CN102584998B (ja)
AU (1) AU2007334531B2 (ja)
BR (1) BRPI0720001A2 (ja)
CA (1) CA2671865C (ja)
CO (1) CO6210756A2 (ja)
ES (1) ES2582655T3 (ja)
IL (2) IL199170A (ja)
IN (1) IN2009CN03372A (ja)
MX (1) MX2009006470A (ja)
NZ (1) NZ578352A (ja)
RU (2) RU2457217C2 (ja)
UA (3) UA95329C2 (ja)
WO (1) WO2008076255A2 (ja)
ZA (1) ZA200904152B (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95329C2 (ru) * 2006-12-14 2011-07-25 Шеринг-Плау Лтд. Собачий тимусный стромальный лимфопоэтин и его применение
JP5492158B2 (ja) * 2011-08-24 2014-05-14 富士フイルム株式会社 ヒトｔｓｈ及び犬ｔｓｈに対する抗体
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
AR090915A1 (es) 2012-05-04 2014-12-17 Intervet Int Bv Proteina de fusion de proteina linfopoyetina estromal timica canina con la region fc de igg
US20160052985A1 (en) * 2013-04-04 2016-02-25 Ieo - Istituto Europeo Di Oncologia Srl Thymic stromal lymphopoietin fragments and uses thereof
PT3031913T (pt) * 2013-08-09 2019-05-31 Astellas Pharma Inc Novo anticorpo anti-receptor de tslp humana
US10023636B2 (en) 2013-12-20 2018-07-17 Intervet Inc. Caninized murine antibodies to human PD-1
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
DK3277722T3 (da) 2015-04-02 2021-10-11 Intervet Int Bv Antistoffer mod canin interleukin-4 receptor alpha
PE20181368A1 (es) 2015-09-09 2018-08-27 Novartis Ag Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE
CN115028722B (zh) * 2021-03-05 2024-09-03 拜西欧斯（北京）生物技术有限公司 抗tslp抗体及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
ZA887773B (en) 1987-10-26 1989-07-26 Immunex Corp Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US6844170B1 (en) 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
ES2288036T5 (es) 1998-11-13 2017-07-06 Immunex Corporation ADN de TSLP humano y polipéptidos
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc SECRETED PROTEINS AND THEIR USES
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
NZ544456A (en) * 2003-07-18 2009-02-28 Schering Corp Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
US20090156467A1 (en) * 2004-07-28 2009-06-18 Zhengbin Yao Thymic stromal lymphpoietin promoter and use therefor
SE532251C2 (sv) 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
UA95329C2 (ru) * 2006-12-14 2011-07-25 Шеринг-Плау Лтд. Собачий тимусный стромальный лимфопоэтин и его применение

Also Published As

Publication number Publication date
JP2012090647A (ja) 2012-05-17
CA2671865C (en) 2017-01-10
UA108064C2 (uk) 2015-03-25
US20130183291A1 (en) 2013-07-18
AU2007334531A1 (en) 2008-06-26
IL199170A (en) 2015-04-30
EP2104683A2 (en) 2009-09-30
US8791242B2 (en) 2014-07-29
WO2008076255A2 (en) 2008-06-26
NZ578352A (en) 2012-05-25
CN101631800A (zh) 2010-01-20
IL215507A0 (en) 2011-11-30
ZA200904152B (en) 2011-11-30
US7718772B2 (en) 2010-05-18
UA95329C2 (ru) 2011-07-25
JP6117767B2 (ja) 2017-04-19
JP2013048637A (ja) 2013-03-14
CA2671865A1 (en) 2008-06-26
EP2104683B1 (en) 2016-05-25
JP5707380B2 (ja) 2015-04-30
AU2007334531B2 (en) 2012-04-12
KR101525631B1 (ko) 2015-06-04
JP2015107121A (ja) 2015-06-11
CN102584998B (zh) 2017-07-04
RU2009126617A (ru) 2011-01-20
CO6210756A2 (es) 2010-10-20
CN102584998A (zh) 2012-07-18
WO2008076255A3 (en) 2008-09-18
US20110033478A1 (en) 2011-02-10
CN101631800B (zh) 2012-12-05
MX2009006470A (es) 2009-06-26
BRPI0720001A2 (pt) 2013-12-24
ES2582655T3 (es) 2016-09-14
KR20090097921A (ko) 2009-09-16
RU2457217C2 (ru) 2012-07-27
RU2617957C2 (ru) 2017-04-28
JP2010512744A (ja) 2010-04-30
US20080152620A1 (en) 2008-06-26
UA120027C2 (uk) 2019-09-25
US8076456B2 (en) 2011-12-13
RU2012113162A (ru) 2013-10-20

Similar Documents

Publication Publication Date Title
IN2009CN03372A (ja)
PH12017501025A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
MX359903B (es) Proteínas estructurales de una mutación del parvovirus como vacunas.
WO2011032161A3 (en) Vaccines directed to langerhans cells
MY162752A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
NZ577828A (en) Human antibodies that bind human il-12 and methods for producing
WO2010104747A3 (en) Antigen presenting cell targeted vaccines
WO2005120565A3 (en) Sars vaccines and methods to produce highly potent antibodies
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
WO2007098201A3 (en) Shiga toxoid chimeric proteins
WO2010104761A3 (en) Anti-cd40 antibodies and uses thereof
NZ600584A (en) Anti-il 17a/il-17f cross-reactive antibodies and methods of use thereof
CU24058B1 (es) Antagonistas de pcsk9
WO2008005880A3 (en) Antibodies for norovirus
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
WO2008130382A3 (en) Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
MX2010001237A (es) Nuevos anticuerpos.
WO2007050095A3 (en) Improved vaccines and methods for using the same
ATE519784T1 (de) An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz
WO2007020520A3 (en) Antigenic peptides and their use
WO2007127372A3 (en) Genetic adjuvants for viral vaccines
AU2005292852A8 (en) Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.
DE602005010680D1 (de) Zusammensetzungen und verfahren zur induktion einer antitumorimmunität
UA100531C2 (ru) Антитело, которое специфически связывается с тимическим стромальным лимфопоэтином (tslp)